| car t therapy for mantle cell lymphoma: The EBMT/EHA CAR-T Cell Handbook Nicolaus Kröger, John Gribben, Christian Chabannon, Ibrahim Yakoub-Agha, Hermann Einsele, 2022-02-07 This first open access European CAR-T Handbook, co-promoted by the European Society for Blood and Marrow Transplantation (EBMT) and the European Hematology Association (EHA), covers several aspects of CAR-T cell treatments, including the underlying biology, indications, management of side-effects, access and manufacturing issues. This book, written by leading experts in the field to enhance readers’ knowledge and practice skills, provides an unparalleled overview of the CAR-T cell technology and its application in clinical care, to enhance readers’ knowledge and practice skills. |
| car t therapy for mantle cell lymphoma: Chimeric Antigen Receptor T-Cell Therapies for Cancer E-Book Daniel W. Lee, Nirali N. Shah, 2019-11-30 From patient referral to post-therapy management, Chimeric Antigen Receptor (CAR) T-Cell Therapies for Cancer: A Practical Guide presents a comprehensive view of CAR modified T-cells in a concise and practical format. Providing authoritative guidance on the implementation and management of CAR T-cell therapy from Drs. Daniel W. Lee and Nirali N. Shah, this clinical resource keeps you up to date on the latest developments in this rapidly evolving area. - Covers all clinical aspects, including patient referral, toxicities management, comorbidities, bridging therapy, post-CAR monitoring, and multidisciplinary approaches to supportive care. - Includes key topics on associated toxicities such as predictive biomarkers, infections, and multidisciplinary approaches to supportive care. - Presents current knowledge on FDA approved CAR T-cell products as well as developments on the horizon. - Editors and authors represent leading investigators in academia and worldwide pioneers of CAR therapy. |
| car t therapy for mantle cell lymphoma: Blood and Marrow Transplant Handbook Richard T. Maziarz, Susan Schubach Slater, 2015-04-20 This updated and expanded edition developed by the Blood and Marrow Stem Cell Transplant team at Oregon Health & Science University Knight Cancer Institute features the latest medical management guidelines and standards of care for hematopoietic stem cell transplant patients. Spanning the timeline from the initial consultation throughout the transplant process, this handbook includes indications for transplantation and donor selection, treatment guidelines for addressing complications during and after transplant, and recommendations for long-term follow up care. Concise, comprehensive, and easy-to-use, Blood and Marrow Transplant Handbook, 2nd Edition presents a multidisciplinary approach to information for physicians and advanced practice medical providers who care for transplant patients, and also residents, fellows, and other trainees. |
| car t therapy for mantle cell lymphoma: Haploidentical Transplantation Stefan O. Ciurea, Rupert Handgretinger, 2018-05-03 In this book, world-renowned experts in the field express well-reasoned opinions on a range of issues and controversies relating to haploidentical transplantation with the aim of providing practicing hematologists with clinically relevant and readily applicable information. Among the areas covered are graft manipulation and methods to control T-cell alloreactivity, the nature of the ideal graft and donor, haploidentical transplantation in pediatric and adult patients with malignant and nonmalignant diseases, immunologic reconstitution following transplantation, complications, and the prevention and treatment of relapse post transplantation. Attention is drawn to the implications of high-impact clinical trials whenever such trials are available. The readily intelligible text is complemented by numerous helpful tables, algorithms, and figures. The book will provide practical support for hematologists and transplant physicians as they attempt to provide optimal care in this exciting but increasingly complex medical specialty. |
| car t therapy for mantle cell lymphoma: Mantle Cell Lymphoma, An Issue of Hematology/Oncology Clinics of North America,E-Book John P. Leonard, 2020-09-11 This issue of Hematology/Oncology Clinics, Guest Edited by Dr. John P. Leonard, is devoted to Mantle Cell Lymphoma. This issue is one of six selected each year by our series Consulting Editors, George P. Canellos and Edward J. Benz. Topics discussed in this important issue include: Molecular pathogenesis of Mantle Cell Lymphoma; MCL and cell cycle dysregulation; Heterogeneity in MCL biology and outcomes; Watch and wait in mantle cell lymphoma; Limited stage mantle cell lymphoma; Initial and consolidation therapy for younger patients with MCL; Approach to the initial treatment of older patients with MCL; Current and future approaches to the use of minimal residual disease monitoring in the treatment of patients with MCL; Bruton's Tyrosine Kinase inhibitors for treatment of Mantle Cell Lymphoma; BTKi resistance in MCL; Blastoid MCL; Allogeneic transplant and CAR-T cell therapy in MCL; Quality of life considerations and chronic therapy in management of patients with MCL; and Key clinical and translational research questions. |
| car t therapy for mantle cell lymphoma: Gene and Cellular Immunotherapy for Cancer Armin Ghobadi, John F. DiPersio, 2022-01-01 Clinical and preclinical exploration of gene and cellular immunotherapy have seen rapid growth and interest with the development and approval of five Chimeric Antigen Receptor T-cell (CAR-T) products for lymphoma and myeloma and one Bispecific T-Cell Engager (BiTE) for acute lymphoblastic leukemia (ALL). These advances have dramatically improved the management of patients with relapsed refractory lymphoma, myeloma and leukemia. Gene and Cellular Immunotherapy for Cancer offers readers a comprehensive review of current cellular and gene-based immunotherapies. Divided into eighteen cohesive chapters, this book provides an in-depth and detailed look into cellular-based immunotherapies including CAR-T, TCR-T, TIL, Viral CTLs, NK cells in addition to T/NK cell engagers, focusing on their historical perspectives, biology, development and manufacturing, toxicities and more. Edited by two leading experts on gene and cellular immunotherapy, the book will feature chapters written by a diverse collection of recognized and up-and-coming experts and researchers in the field, providing oncologists, immunologists, researchers and clinical and basic science trainees with a bench to bedside view of the latest developments in the field. |
| car t therapy for mantle cell lymphoma: The EBMT Handbook Nicolaus Kröger, Mohamad Mohty, Carlo Dufour, 2020-10-08 This Open Access edition of the European Society for Blood and Marrow Transplantation (EBMT) handbook addresses the latest developments and innovations in hematopoietic stem cell transplantation and cellular therapy. Consisting of 93 chapters, it has been written by 175 leading experts in the field. Discussing all types of stem cell and bone marrow transplantation, including haplo-identical stem cell and cord blood transplantation, it also covers the indications for transplantation, the management of early and late complications as well as the new and rapidly evolving field of cellular therapies. This book provides an unparalleled description of current practices to enhance readers' knowledge and practice skills. This work was published by Saint Philip Street Press pursuant to a Creative Commons license permitting commercial use. All rights not granted by the work's license are retained by the author or authors. |
| car t therapy for mantle cell lymphoma: Protein Engineering Huimin Zhao, 2021-08-23 A one-stop reference that reviews protein design strategies to applications in industrial and medical biotechnology Protein Engineering: Tools and Applications is a comprehensive resource that offers a systematic and comprehensive review of the most recent advances in the field, and contains detailed information on the methodologies and strategies behind these approaches. The authors—noted experts on the topic—explore the distinctive advantages and disadvantages of the presented methodologies and strategies in a targeted and focused manner that allows for the adaptation and implementation of the strategies for new applications. The book contains information on the directed evolution, rational design, and semi-rational design of proteins and offers a review of the most recent applications in industrial and medical biotechnology. This important book: Covers technologies and methodologies used in protein engineering Includes the strategies behind the approaches, designed to help with the adaptation and implementation of these strategies for new applications Offers a comprehensive and thorough treatment of protein engineering from primary strategies to applications in industrial and medical biotechnology Presents cutting edge advances in the continuously evolving field of protein engineering Written for students and professionals of bioengineering, biotechnology, biochemistry, Protein Engineering: Tools and Applications offers an essential resource to the design strategies in protein engineering and reviews recent applications. |
| car t therapy for mantle cell lymphoma: Multiparameter Flow Cytometry in the Diagnosis of Hematologic Malignancies Anna Porwit, Marie Christine Béné, 2018-01-25 Master implementation of the techniques of flow cytometry in diagnosing complex haematological diseases and malignancies in patients, worldwide. Featuring World Health Organization recommendations on pre-analytical steps, instrument settings and panel construction, this invaluable manual offers invaluable support for those researching, practising and analyzing the cause of hematological malignancies. Authored by leading experts, this book puts flow-cytometry into everyday context. With a focus on multicolour panels, the manual provides readers an experienced understanding of effective, implementation techniques. Practitioners of all levels are offered a background in a variety of diseases presented alongside the most current methodology. Wide-ranging and comprehensive; detailed images of healthy blood, bone marrow and lymph-nodes are illustrated throughout, allowing for effective diagnosis. Through engaging with differential diagnoses, the manual offers an understanding of similar symptoms and mimicking malignancies, avoiding inaccurate results. Featuring in-depth descriptions of chronic diseases; users can reach accurate diagnosis, first time. |
| car t therapy for mantle cell lymphoma: Heparanase Israel Vlodavsky, Ralph D. Sanderson, Neta Ilan, 2020-04-09 Written by internationally recognized leaders in Heparanase biology, the book’s eight chapters offer an opportunity for scientists, clinicians and advanced students in cell biology, tumor biology and oncology to obtain a comprehensive understanding of Heparanase’s multifaceted activities in cancer, inflammation, diabetes and other diseases, as well as its related clinical applications. Proteases and their involvement in cancer progression have been well addressed and documented; however, the emerging premise presented within this book is that Heparanase is a master regulator of aggressive cancer phenotypes and crosstalk with the tumor microenvironment. This endoglycosidase contributes to tumor-mediated remodeling of the extracellular matrix and cell surfaces, augmenting the bioavailability of pro-tumorigenic and pro-inflammatory growth factors and cytokines that are bound to Heparan sulfate. Compelling evidence ties Heparanase with all steps of tumor progression including tumor initiation, growth, angiogenesis, metastasis, and chemoresistance, supporting the notion that Heparanase is an important contributor to the poor outcome of cancer patients and a validated target for therapy. Unlike Heparanase, heparanase-2, a close homolog of Heparanase, lacks enzymatic activity, inhibits Heparanase, and regulates selected genes that promote normal differentiation and tumor suppression. Written by internationally recognized leaders in Heparanase biology, this volume presents a comprehensive understanding of Heparanase’s multifaceted activities in cancer, inflammation, diabetes and other diseases, as well as its related clinical applications to scientists, clinicians and advanced students in cell biology, tumor biology and oncology. |
| car t therapy for mantle cell lymphoma: Co-signal Molecules in T Cell Activation Miyuki Azuma, Hideo Yagita, 2019-11-22 This book equips young immunologists and health professionals with a clear understanding of the fundamental concepts and roles of co-signal molecules and in addition presents the latest information on co-stimulation. The first part of the book is devoted to co-signal molecules and the regulation of T cells. Following an initial overview, subsequent chapters examine each co-signal molecule in turn and discuss the mechanisms by which co-signal molecules regulate the different types of T cell. The second part covers various clinical applications, including in autoimmune disease, neurological disorders, transplantation, graft-versus-host disease, and cancer immunotherapy. To date, co-stimulation blockade and co-inhibition blockade have shown beneficial effects and many additional clinical trials targeting co-signal molecules are ongoing. The mechanisms underlying these successful treatments are explained and the future therapeutic potential in the aforementioned diseases is evaluated. Co-signal Molecules in T Cell Activation will be a valuable reference guide to co-stimulation for basic and clinical researchers in the fields of both immunology and pharmaceutical science. |
| car t therapy for mantle cell lymphoma: Histopathology of Non-Hodgkin's Lymphomas Karl Lennert, Alfred C. Feller, 1990 |
| car t therapy for mantle cell lymphoma: Lymphoma Anas Younes, Bertrand Coiffier, 2013-05-17 Recently, understanding the molecular pathogenesis of malignant lymphomas has led to improvement in the diagnostic precision and to the identification of a variety of molecular therapeutic targets. In addition, new drugs have been approved in the US and Europe, resulting in changes in the standard of care of several types of lymphoid malignancies. Comprehensive in scope and developed by a team of internationally renowned authors, Lymphoma: Diagnosis and Treatment provides a timely update on the most important advances in the biology, diagnosis, and therapy of lymphomas. As part of the Current Clinical Oncology series, Lymphoma: Diagnosis and Treatment will be of value to medical oncologists, hematologists, radiation oncologists, and all physicians involved in the care of patients with lymphoid malignancies. |
| car t therapy for mantle cell lymphoma: The Peripheral T-Cell Lymphomas Owen A. O'Connor, Won Seog Kim, Pier L. Zinzani, 2021-06-01 THE PERIPHERAL T-CELL LYMPHOMAS Provides a comprehensive look at Peripheral T-Cell lymphomas, including the group’s unique geographic distribution, underlying genetics, and novel treatments Peripheral T-Cell lymphomas (PTCL) are a diverse group of lymphoid malignancies that develop from mature T cells and natural killer (NK) cells. PTCL represent 10-15% of all cases of non-Hodgkin lymphoma in the US, and up to 20-25% of cases in South America, Asia, and other regions around the world. The role of different etiologic factors and the variation of geographic distribution makes PTCL one of the most difficult types of cancer to understand and treat. For the first time in a single volume, The Peripheral T-Cell Lymphomas presents a comprehensive survey of this complex and rare group of blood cancers. Featuring contributions from an international team of leading authorities in the various aspects of PTCL, this authoritative text covers biology, epidemiology, classification, approved and emerging drugs, molecular genetics, and more. Detailed clinical chapters address diagnosis, prognosis, and treatment of each of the major PTCL subtypes identified in the 2018 WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues. This much-needed resource: Covers the biological basis, epidemiology, classification, and treatment of PTCL Discusses the future of the field, including global collaboration efforts and novel approaches to PCTL Explores the role of biologics in PTCL and autologous and allogeneic stem-cell transplantation Offers new insights on molecular pathogenesis, innovative therapeutics, and novel drug combinations Features contributions from the Chairs The T-Cell Lymphoma Forum: the world’s largest meeting focused on PTCL Reflecting the unique epidemiology and genetic diversity of the PTCL, The Peripheral T-Cell Lymphomas is an indispensable source of data, insight, and references for the medical community, particularly oncologists and hematologists in both training and practice. |
| car t therapy for mantle cell lymphoma: Guidelines for Preparing Patent Landscape Reports World Intellectual Property Organization, 2015-08-24 These Guidelines are designed both for general users of patent information, as well as for those involved in producing Patent Landscape Reports (PLRs). They provide step-by-step instructions on how to prepare a PLR, as well as background information such as objectives, patent analytics, concepts and frameworks. |
| car t therapy for mantle cell lymphoma: Treatment of Leukemia and Lymphoma David A. Scheinberg, Joseph G. Jurcic, 2004-10-30 New Treatments of Leukemia and Lymphoma describes the most important advances in the therapy of hematopoietic cancers that have been derived from recent discoveries in cancer cell biology, kinase biochemistry, and immunology. Detailed descriptions of the large number of new and effective agents that have recently become available for the treatment of leukemias and lymphomas as well as an understanding of their mechanisms of action and their integration into current therapy are provided. A number of experimental drug reagents currently in clinical investigation are also discussed. The therapies include conventional anti-metabolites, monoclonal antibodies directed to cell surface receptors, antibodies tagged with toxins and radiopharmaceuticals, inhibitors of specific kinases, stem cell transplants, and engineered T-cells designed to selectively target hematopoietic cancers. The contents of the book will allow practitioners and investigators alike to understand what is current and state of the art as well as what to look for in the future.* Provides an up-to-date, state of the art discussion of a rapidly changing field * Great breadth covering conventional chemotherapeutic agents, biologic agents such as antibodies, novel small molecule inhibitors and genetically engineered cells * Written by international experts in each of the fields |
| car t therapy for mantle cell lymphoma: Immunopharmacogenomics Yusuke Nakamura, 2015-09-18 This book proposes immunogenomics, or immunopharmacogenomics, as the next-generation big science to uncover the role that the immune system plays in the pathogenesis of many diseases, by summarizing the importance of the deep sequencing of T-cell and B-cell receptors. Immunogenomics/immunopharmacogenomics, a genetic characterization of the immune system made possible by next-generation sequencing (NGS), will be important for the further understanding of the pathogenesis of various disease conditions. Abnormal immune responses in the body lead to development of autoimmune diseases and food allergies. Rejection of recipient cells and tissues, as well as severe immune reactions to donor cells, is also the result of uncontrolled immune responses in the recipient body. There have been many reports indicating that activated immune responses caused by the interaction of drugs and HLA are present in drug-induced skin hypersensitivity and liver toxicity. The importance of the host immune responses has been recognized in cancer treatments, not only for immunotherapy but also for cytotoxic agents and molecular targeted drugs. Hence, characterization of the T-cell receptor and B-cell receptor repertoire by means of NGS deep sequencing will ultimately make possible the identification of the molecular mechanisms that underlie various diseases and drug responses. In addition, this approach may contribute to the identification of antigens associated with the onset or progression of autoimmune diseases as well as food allergies. Although the germline alterations and somatic mutations have been extensively analyzed, changes or alterations of the immune responses during the course of various disease conditions or during various treatments have not been analyzed. It is also clear that computational analyses to draw meaningful inferences of functional recognition receptors on the immune cells remain a huge challenge. |
| car t therapy for mantle cell lymphoma: SITC’s Guide to Managing Immunotherapy Toxicity Marc S. Ernstoff, MD, Igor Puzanov, MD, MSCI, FACP, Caroline Robert, MD, PhD, Adi M. Diab, MD, Peter M. Hersey, MD, PhD, 2019-03-15 The Society for Immunotherapy of Cancer's handbook,SITC’s Guide to Managing Immunotherapy Toxicity, is a practical reference to managing side effects associated with FDA-approved cancer immunotherapy drugs. Separated into two parts, Part I contains chapter-based overviews of immune checkpoint inhibitors in the clinic, starting with anti-CTLA4 agents, anti-PD1/PD-L1 agents, and approved immunotherapeutic combinations. These chapters cover relevant mechanisms of action, indications, and toxicities seen while combating early, advanced, and metastatic stages in cancer patients. Part II is structured by common and uncommon toxicities that affect major organ sites throughout the body. It begins with a general summary of principles and management options followed by chapters focusing on specific toxicities such as rash and mucosal irritation, muscle and joint toxicity, diarrhea and colitis, pneumonitis, endocrine toxicities, neurological toxicities, cardiac toxicity, renal toxicity, hematologic toxicity, and ocular toxicities. Each chapter provides guidance on how to assess and treat the toxicity and how to support the patient through acute and chronic effects with detailed summary tables for quick reference. Part II concludes with chapters covering management of special patient populations, including patients with autoimmune disease and geriatric patients, treatment and management of fatigue, and a final chapter dedicated to cost effectiveness and the toll of financial toxicity on patients and caregivers. With chapters written by world-recognized leaders in the immuno-oncology field, this text provides thorough coverage of the toxicity and management of adverse effects for immune checkpoint inhibitors. It is an indispensable resource for clinical oncologists, emergency physicians, hospitalists and other medical practitioners in both the hospital and community clinic settings, especially as the use of immune checkpoint inhibitors becomes a fixture in oncology care. Key Features: Outlines strategies for treating high-risk patients facing an acute or chronic side effect to immunotherapy Provides numerous tables that condense and highlight pertinent information for quick reference Describes the various clinical presentations and toxic reactions caused by immunotherapy Purchase includes access to the eBook for use on most mobile devices or computer |
| car t therapy for mantle cell lymphoma: Oncoimmunology Laurence Zitvogel, Guido Kroemer, 2017-12-13 In this book, leading experts in cancer immunotherapy join forces to provide a comprehensive guide that sets out the main principles of oncoimmunology and examines the latest advances and their implications for clinical practice, focusing in particular on drugs with FDA/EMA approvals and breakthrough status. The aim is to deliver a landmark educational tool that will serve as the definitive reference for MD and PhD students while also meeting the needs of established researchers and healthcare professionals. Immunotherapy-based approaches are now inducing long-lasting clinical responses across multiple histological types of neoplasia, in previously difficult-to-treat metastatic cancers. The future challenges for oncologists are to understand and exploit the cellular and molecular components of complex immune networks, to optimize combinatorial regimens, to avoid immune-related side effects, and to plan immunomonitoring studies for biomarker discovery. The editors hope that this book will guide future and established health professionals toward the effective application of cancer immunology and immunotherapy and contribute significantly to further progress in the field. |
| car t therapy for mantle cell lymphoma: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues World Health Organization, 2001 This is the third volume in the new World Health Organization series on histological and genetic typing of tumours. Tumours of the haematopoietic and lymphoid tissues are covered. This was a collaborative project of the European Association for Haematolpathology and the Society for Haematopathology and others. The WHO classification is based on the principles defined in the Revised European-American Classification of Lymphoid Neoplasms (REAL) classification. Over 50 pathologists from around the world were involved in the project and proponents of all major lymphoma and leukaemia classifications have agreed to accept the WHO as the standard classification of haematological malignancies. So this classification represents the first true world wide concensus of haematologic malignancies. Colour photographs, magnetic resonance and ultrasound images and CT scans are included. |
| car t therapy for mantle cell lymphoma: Cell and Gene Therapies Miguel-Angel Perales, Syed A. Abutalib, Catherine Bollard, 2018-11-27 In this book, experts in the field express their well-reasoned opinions on a range of complex, clinically relevant issues across the full spectrum of cell and gene therapies with the aim of providing trainee and practicing hematologists, including hematopoietic transplant physicians, with information that is relevant to clinical practice and ongoing research. Each chapter focuses on a particular topic, and the concise text is supported by numerous working tables, algorithms, and figures. Whenever appropriate, guidance is provided regarding the availability of potentially high-impact clinical trials. The rapid evolution of cell and gene therapies is giving rise to numerous controversies that need to be carefully addressed. In meeting this challenge, this book will appeal to all residents, fellows, and faculty members responsible for the care of hematopoietic cell transplant patients. It will also offer a robust, engaging tool to aid vital activities in the daily work of every hematology and oncology trainee. |
| car t therapy for mantle cell lymphoma: Handbook of Hematologic Malignancies David A. Sallman, Ateefa Chaudhury, Johnny Nguyen, Ling Zhang, Alan F. List, 2017 MDS/MPN With Ring Sideroblasts and Thrombocytosis |
| car t therapy for mantle cell lymphoma: Mechanisms of Drug Resistance in Neoplastic Cells Paul V. Woolley, Kenneth D. Tew, 2013-10-22 Bristol-Myers Cancer Symposia, Volume 9: Mechanisms of Drug Resistance in Neoplastic Cells provides information on both basic scientific and clinical studies on the causes and implications of tumor cell resistance to common antineoplastic agents. The book describes the colon cancer as a model for resistance to antineoplastic drugs; mathematical modeling of drug resistance; and the mechanism of induced gene amplification in mammalian cells. The text also discusses the cellular concomitants of multidrug resistance; resistance to alkylating agents; and the phosphoprotein and protein kinase C changes in human multidrug-resistant cancer cells. Novel drugs that affect glutathione metabolism; the regulation of genes encoding drug-metabolizing enzymes in normal and preneoplastic tissues; and the relevance of glutathione S-transferases to anticancer drug resistance are also considered. The book further tackles the cellular resistance to cyclophosphamide; the preclinical and clinical experiences with drug combinations designed to inhibit DNA repair in resistant human tumor cells; and the modification of the cytotoxicity of DNA-directed chemotherapeutic agents by polyamine depletion. The text also demonstrates multidrug resistance and the circumvention of resistance. Oncologists, molecular biologists, biochemists, geneticists, and pharmacologists will find the book invaluable. |
| car t therapy for mantle cell lymphoma: Brain Tumor Imaging Elke Hattingen, Ulrich Pilatus, 2015-09-02 This book describes the basics, the challenges and the limitations of state of the art brain tumor imaging and examines in detail its impact on diagnosis and treatment monitoring. It opens with an introduction to the clinically relevant physical principles of brain imaging. Since MR methodology plays a crucial role in brain imaging, the fundamental aspects of MR spectroscopy, MR perfusion and diffusion-weighted MR methods are described, focusing on the specific demands of brain tumor imaging. The potential and the limits of new imaging methodology are carefully addressed and compared to conventional MR imaging. In the main part of the book, the most important imaging criteria for the differential diagnosis of solid and necrotic brain tumors are delineated and illustrated in examples. A closing section is devoted to the use of MR methods for the monitoring of brain tumor therapy. The book is intended for radiologists, neurologists, neurosurgeons, oncologists and other scientists in the biomedical field with an interest in neuro-oncology. |
| car t therapy for mantle cell lymphoma: Immunologic Concepts in Transfusion Medicine Robert W Maitta, 2019-08-27 Immunological Concepts in Transfusion Medicine provides a thorough discussion of the immune aspects of blood component transfusion, with in-depth information on the intricacies of immune responses to blood components and the immune processes that may be initiated in response to blood exposure. Written to increase knowledge and awareness of immune challenges such as alloimmunization and transfusion-related acute lung injury, this title bridges current basic scientific discoveries and the potential effects seen in blood recipients. - Complies the knowledge and expertise of Dr. Robert Maitta, an expert in immune responses and antibody function/structure studies. - Helps clinicians in the daily practice of caring for patients in need of transfusion support, as well as physicians in training when considering utilizing blood transfusions in a limited scope or in the setting of massive transfusion. - Includes an immunology primer as an introduction to in-depth chapters covering allergic immune reactions to blood components, transfusion-related immunomodulation, fetal and neonatal alloimmune thrombocytopenia and neonatal neuthropenia, complications of haploidentical and mismatched HSC transplantation, chimeric antibody receptor therapies, and much more. - Consolidates today's available information on this timely topic into a single, convenient resource. |
| car t therapy for mantle cell lymphoma: Adoptive Immunotherapy Burkhard Ludewig, Matthias W. Hoffmann, 2008-02-02 An authoritative collection of optimal techniques for producing and characterizing the immunologically active cells and effector molecules now gaining wide use in the clinical treatment of patients. Taking advantage of the latest technologies, the authors present readily reproducible experimental protocols for the study of dendritic cells, T cells, monoclonal antibodies, and bone marrow transplantation. The emphasis is on preclinicical and clinical applications and on the progress of selected approaches in clinical trials. Additional chapters cover the molecular definition of target antigens, mathematical modeling approaches to immunotherapy, and the utilization of regulatory T cells. The protocols make it possible to study the adoptive transfer of tailored antigen-specific immune cells and to improve the clinical application of adoptive immunotherapy. |
| car t therapy for mantle cell lymphoma: Pediatric Lymphomas Howard J. Weinstein, Melissa M. Hudson, Michael P. Link, 2007-01-20 This is a comprehensive textbook of Hodgkin's and non-Hodgkin's lymphomas written by leaders in the field of childhood lymphomas. It includes clinical, pathologic and molecular biology of each subtype of lymphoma. The pathology chapters are comprehensive and include excellent photographs. The book is at the level of subspecialists in pediatric hematology and oncology, radiation oncology, pediatric surgery and hematopathology. |
| car t therapy for mantle cell lymphoma: Current Strategies in Cancer Gene Therapy Wolfgang Walther, 2017-01-17 This book describes important developments and emerging trends in experimental and clinical cancer gene therapy. It reflects the tremendous advances made over recent years with respect to immunogenes, suicide genes and gene correction therapies, as well as in gene suppression and miRNA therapies. Many of the described strategies focus on the generation of more efficient and specific means of attack at known and novel cellular targets associated with tumor development and progression. The book also details parallel improvements in vector design, vector delivery, and therapeutic efficacy. It offers readers a stimulating, broad overview of advances in the field, linking experimental strategies to their clinical applications. |
| car t therapy for mantle cell lymphoma: Cancer-Associated Thrombosis Alok A. Khorana, Charles W. Francis, 2007-09-26 Showcasing the expertise of top-tier specialists who contributed to the newly released guidelines for the care of thrombosis in cancer patients, this exciting guide was written and edited by members of the American Society of Clinical Oncology panel, (ASCO), on the prevention and treatment of cancer-associated thrombosis, among others, and provides |
| car t therapy for mantle cell lymphoma: Cancer Incidence and Survival Among Children and Adolescents , 1999 |
| car t therapy for mantle cell lymphoma: Hematopoietic Stem Cell Transplantation for the Pediatric Hematologist/Oncologist Valerie I. Brown, 2017-12-22 This volume provides a comprehensive and state-of-the-art review on pediatric hematopoietic stem cell transplantation (HSCT). The book covers such topics as graft versus host disease (GVHD), HSC mobilization, stem cell selection, and HSCT-relevant laboratory assays and techniques. The text is specially formatted so that the scientific basis of HSCT and ethical considerations are integrated into the relevant clinical framework. Each chapter also includes diagrams, illustrations, and tables that summarize key points and concepts that can be used as a quick visual reference for the reader. Written by experts in the field, Hematopoietic Stem Cell Transplantation for the Pediatric Hematologist/Oncologist is a valuable resource on pediatric HSCT suited for pediatric hematologists-oncologists, fellows, advanced practitioners, clinical nurses, and other referring physicians. |
| car t therapy for mantle cell lymphoma: Mantle Cell Lymphoma, an Issue of Hematology/Oncology Clinics of North America, Volume 34-5 John P. Leonard, 2020-10-28 This issue of Hematology/Oncology Clinics, Guest Edited by Dr. John P. Leonard, is devoted to Mantle Cell Lymphoma. This issue is one of six selected each year by our series Consulting Editors, George P. Canellos and Edward J. Benz. Topics discussed in this important issue include: Molecular pathogenesis of Mantle Cell Lymphoma; MCL and cell cycle dysregulation; Heterogeneity in MCL biology and outcomes; Watch and wait in mantle cell lymphoma; Limited stage mantle cell lymphoma; Initial and consolidation therapy for younger patients with MCL; Approach to the initial treatment of older patients with MCL; Current and future approaches to the use of minimal residual disease monitoring in the treatment of patients with MCL; Bruton's Tyrosine Kinase inhibitors for treatment of Mantle Cell Lymphoma; BTKi resistance in MCL; Blastoid MCL; Allogeneic transplant and CAR-T cell therapy in MCL; Quality of life considerations and chronic therapy in management of patients with MCL; and Key clinical and translational research questions. |
| car t therapy for mantle cell lymphoma: CAR T-Cell, An Issue of Hematology/Oncology Clinics of North America, E-Book Caron A Jacobson, Parth S. Shah, 2023-10-12 In this issue of Hematology/Oncology Clinics, guest editors Drs. Caron A. Jacobson and Parth S. Shah bring their considerable expertise to the topic of CAR T-Cell Therapy. Top experts in the field discuss the multiple ways CAR T-cell therapy can be used to help fight a variety of cancers, such as diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, mantle cell lymphoma, multiple myeloma, and B-cell acute lymphoblastic leukemia (ALL). - Contains 12 practice-oriented topics including CAR T-cells in aggressive B-cell lymphomas; CAR T-cells in multiple myeloma; CAR T-cells in AML; mechanisms of resistance of CAR T-cell therapy; the role of CAR T-cell therapy in the era of bispecific antibodies; and more. - Provides in-depth clinical reviews on CAR T-cell therapy, offering actionable insights for clinical practice. - Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews. |
| car t therapy for mantle cell lymphoma: Car T-Cell T, an Issue of Hematology/Oncology Clinics of North America: Volume 37-6 Caron A. Jacobson, Parth S. Shah, 2023-12-28 In this issue of Hematology/Oncology Clinics, guest editors Drs. Caron A. Jacobson and Parth S. Shah bring their considerable expertise to the topic of CAR T-Cell Therapy. Top experts in the field discuss the multiple ways CAR T-cell therapy can be used to help fight a variety of cancers, such as diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, mantle cell lymphoma, multiple myeloma, and B-cell acute lymphoblastic leukemia (ALL). Contains 12 practice-oriented topics including CAR T-cells in aggressive B-cell lymphomas; CAR T-cells in multiple myeloma; CAR T-cells in AML; mechanisms of resistance of CAR T-cell therapy; the role of CAR T-cell therapy in the era of bispecific antibodies; and more. Provides in-depth clinical reviews on CAR T-cell therapy, offering actionable insights for clinical practice. Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews. |
| car t therapy for mantle cell lymphoma: DeVita, Hellman, and Rosenberg's Cancer Vincent T DeVita Jr, Steven A Rosenberg, Theodore S Lawrence, 2022-09-21 The standard-setting text in oncology for 40 years, DeVita, Hellman and Rosenberg’s Cancer: Principles and Practice of Oncology, 12th Edition, provides authoritative guidance and strategies for managing every type of cancer by stage and presentation. Drs. Vincent T. DeVita, Jr., Theodore S. Lawrence, and Steven A. Rosenberg oversee an outstanding team of expert contributing authors who keep you up to date and fully informed in this fast-changing field. This award-winning reference is also continually updated on Health Library and VitalSource platforms for the life of the edition. |
| car t therapy for mantle cell lymphoma: MCB: CAR T Cells: Development, Characterization and Applications Lorenzo Galluzzi, Sheila Spada, 2022-02-11 MCB: CAR T Cells: Development, Characterization and Applications, Volume 167 in the Methods in Cell Biology series, highlights new advances in the field, with this new volume presenting interesting chapters on a variety of timely topics, including High-efficiency of genetic modification using CRISPR/Cpf1 system for engineered CAR T-cell therapy, Determination of the Biodistribution of Chimeric Antigen Receptor-Modified T Cells against CD19 in NSG Mice, Generation of CAR-T cells using lentiviral vectors, Generation of CAR T-cells using ?-retroviral vector, Flow cytometry detection and quantification of CAR T cells into solid tumors, Evaluation of CAR-T Cell Cytotoxicity: Real-Time Impedance-Based Analysis, and much more. - Provides the authority and expertise of leading contributors from an international board of authors - Presents the latest release in the Methods in Cell Biology series - Includes the latest information on the topic of development, characterization and applications in CAR T Cells |
| car t therapy for mantle cell lymphoma: Novel therapies for indolent lymphomas in the cellular therapy era Narendranath Epperla, Sairah Ahmed, 2023-11-06 |
| car t therapy for mantle cell lymphoma: Constructing new motifs in hematology Erden Atilla, Mutlu Arat, Gunhan Gurman, 2023-06-29 |
| car t therapy for mantle cell lymphoma: Fast Facts: CAR T-Cell Therapy Richard J. Buka, Ankit J. Kansagra, 2021-02-28 Chimeric antigen receptor (CAR) T cells are genetically engineered immune cells that can seek out and destroy cancer cells. The results from their use in cancer immunotherapy have been very promising, but treatment is often associated with frequent, serious short-term toxicities. 'Fast Facts: CAR-T Therapy' explains what CAR T cells are and how they were developed, discusses the results of clinical trials and the management of toxicities, and outlines future improvements and applications. It is ideal reading for any healthcare professional wanting to know more about this exciting therapeutic field. Table of Contents: • CAR T cells • Clinical application • Practical aspects • Future directions |
| car t therapy for mantle cell lymphoma: Hematology E-Book Ronald Hoffman, Edward J. Benz, Leslie E. Silberstein, Helen Heslop, Jeffrey Weitz, Mohamed E. Salama, Syed Ali Abutalib, 2022-10-27 Extensively revised, comprehensive content from leading global contributors ensures that Hematology, 8th Edition, remains your #1 choice for expert guidance in all areas of this rapidly advancing subspecialty. This edition reflects the numerous advances that are redefining the field and dramatically influencing new approaches to diagnosis, treatment, and outcomes. Well-illustrated and clinically focused, it details the basic science and clinical practice of hematology and hematopoietic cellular therapy—covering virtually all aspects of hematology in one definitive resource. - Covers all hematologic disorders, including comprehensive discussions of hematologic malignancies, individualized patient care, cell-based therapies, transplantation, transfusion medicine, hemostasis, thrombosis, and consultative hematology—in one convenient volume. - Provides state-of-the-art guidance from global experts at the forefront of the latest research and clinical practice. - Provides extensive updates throughout on basic science research, advances in molecular diagnostics, new drugs, immunotherapies, personalized medicine, laboratory medicine, transfusion medicine, stem cell transplantation, and clinical treatment for all hematologic malignancies and non-malignancies - Contains new chapters on gene editing; the impact of mitochondria on hematopoiesis; myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes; immunotherapy and management of its toxicities; transfusion medicine in sickle cell disease; principles of radiation therapy; and COVID-19, including complications of vaccination and its impact on the hematologic system. - Discusses many new advances in the field, including details and the future of gene therapy for hemophilia, gene editing for sickle cell disease and thalassemia, the evolution of cellular therapy, use of cells, transfusion medicine vs. protein therapy, gene sequencing, immunotherapy, and new targeted drugs. - Includes more decision-making algorithms for formulating diagnoses and personalized treatment plans for those highly complex disorders that require individualized approaches. - Addresses the effects of aging on hematopoiesis and on the manifestations of a variety of hematologic disorders. - Discusses cardio-oncology and its impact on the treatment of patients with hematologic disorders. - Presents relevant basic science as background for clinical application in later sections. - An eBook version is included with purchase. The eBook allows you to access all of the text, figures and references, with the ability to search, customize your content, make notes and highlights, and have content read aloud. |
| car-t therapy for mantle cell lymphoma: The EBMT/EHA CAR-T Cell Handbook Nicolaus Kröger, John Gribben, Christian Chabannon, Ibrahim Yakoub-Agha, Hermann Einsele, 2022-02-07 This first open access European CAR-T Handbook, co-promoted by the European Society for Blood and Marrow Transplantation (EBMT) and the European Hematology Association (EHA), covers several aspects of CAR-T cell treatments, including the underlying biology, indications, management of side-effects, access and manufacturing issues. This book, written by leading experts in the field to enhance readers’ knowledge and practice skills, provides an unparalleled overview of the CAR-T cell technology and its application in clinical care, to enhance readers’ knowledge and practice skills. |
| car-t therapy for mantle cell lymphoma: Chimeric Antigen Receptor T-Cell Therapies for Cancer E-Book Daniel W. Lee, Nirali N. Shah, 2019-11-30 From patient referral to post-therapy management, Chimeric Antigen Receptor (CAR) T-Cell Therapies for Cancer: A Practical Guide presents a comprehensive view of CAR modified T-cells in a concise and practical format. Providing authoritative guidance on the implementation and management of CAR T-cell therapy from Drs. Daniel W. Lee and Nirali N. Shah, this clinical resource keeps you up to date on the latest developments in this rapidly evolving area. - Covers all clinical aspects, including patient referral, toxicities management, comorbidities, bridging therapy, post-CAR monitoring, and multidisciplinary approaches to supportive care. - Includes key topics on associated toxicities such as predictive biomarkers, infections, and multidisciplinary approaches to supportive care. - Presents current knowledge on FDA approved CAR T-cell products as well as developments on the horizon. - Editors and authors represent leading investigators in academia and worldwide pioneers of CAR therapy. |
| car-t therapy for mantle cell lymphoma: Blood and Marrow Transplant Handbook Richard T. Maziarz, Susan Schubach Slater, 2015-04-20 This updated and expanded edition developed by the Blood and Marrow Stem Cell Transplant team at Oregon Health & Science University Knight Cancer Institute features the latest medical management guidelines and standards of care for hematopoietic stem cell transplant patients. Spanning the timeline from the initial consultation throughout the transplant process, this handbook includes indications for transplantation and donor selection, treatment guidelines for addressing complications during and after transplant, and recommendations for long-term follow up care. Concise, comprehensive, and easy-to-use, Blood and Marrow Transplant Handbook, 2nd Edition presents a multidisciplinary approach to information for physicians and advanced practice medical providers who care for transplant patients, and also residents, fellows, and other trainees. |
| car-t therapy for mantle cell lymphoma: Haploidentical Transplantation Stefan O. Ciurea, Rupert Handgretinger, 2018-05-03 In this book, world-renowned experts in the field express well-reasoned opinions on a range of issues and controversies relating to haploidentical transplantation with the aim of providing practicing hematologists with clinically relevant and readily applicable information. Among the areas covered are graft manipulation and methods to control T-cell alloreactivity, the nature of the ideal graft and donor, haploidentical transplantation in pediatric and adult patients with malignant and nonmalignant diseases, immunologic reconstitution following transplantation, complications, and the prevention and treatment of relapse post transplantation. Attention is drawn to the implications of high-impact clinical trials whenever such trials are available. The readily intelligible text is complemented by numerous helpful tables, algorithms, and figures. The book will provide practical support for hematologists and transplant physicians as they attempt to provide optimal care in this exciting but increasingly complex medical specialty. |
| car-t therapy for mantle cell lymphoma: Mantle Cell Lymphoma, An Issue of Hematology/Oncology Clinics of North America,E-Book John P. Leonard, 2020-09-11 This issue of Hematology/Oncology Clinics, Guest Edited by Dr. John P. Leonard, is devoted to Mantle Cell Lymphoma. This issue is one of six selected each year by our series Consulting Editors, George P. Canellos and Edward J. Benz. Topics discussed in this important issue include: Molecular pathogenesis of Mantle Cell Lymphoma; MCL and cell cycle dysregulation; Heterogeneity in MCL biology and outcomes; Watch and wait in mantle cell lymphoma; Limited stage mantle cell lymphoma; Initial and consolidation therapy for younger patients with MCL; Approach to the initial treatment of older patients with MCL; Current and future approaches to the use of minimal residual disease monitoring in the treatment of patients with MCL; Bruton's Tyrosine Kinase inhibitors for treatment of Mantle Cell Lymphoma; BTKi resistance in MCL; Blastoid MCL; Allogeneic transplant and CAR-T cell therapy in MCL; Quality of life considerations and chronic therapy in management of patients with MCL; and Key clinical and translational research questions. |
| car-t therapy for mantle cell lymphoma: Gene and Cellular Immunotherapy for Cancer Armin Ghobadi, John F. DiPersio, 2022-01-01 Clinical and preclinical exploration of gene and cellular immunotherapy have seen rapid growth and interest with the development and approval of five Chimeric Antigen Receptor T-cell (CAR-T) products for lymphoma and myeloma and one Bispecific T-Cell Engager (BiTE) for acute lymphoblastic leukemia (ALL). These advances have dramatically improved the management of patients with relapsed refractory lymphoma, myeloma and leukemia. Gene and Cellular Immunotherapy for Cancer offers readers a comprehensive review of current cellular and gene-based immunotherapies. Divided into eighteen cohesive chapters, this book provides an in-depth and detailed look into cellular-based immunotherapies including CAR-T, TCR-T, TIL, Viral CTLs, NK cells in addition to T/NK cell engagers, focusing on their historical perspectives, biology, development and manufacturing, toxicities and more. Edited by two leading experts on gene and cellular immunotherapy, the book will feature chapters written by a diverse collection of recognized and up-and-coming experts and researchers in the field, providing oncologists, immunologists, researchers and clinical and basic science trainees with a bench to bedside view of the latest developments in the field. |
| car-t therapy for mantle cell lymphoma: The Heterogeneity of Cancer Metabolism Anne Le, 2018-06-26 Genetic alterations in cancer, in addition to being the fundamental drivers of tumorigenesis, can give rise to a variety of metabolic adaptations that allow cancer cells to survive and proliferate in diverse tumor microenvironments. This metabolic flexibility is different from normal cellular metabolic processes and leads to heterogeneity in cancer metabolism within the same cancer type or even within the same tumor. In this book, we delve into the complexity and diversity of cancer metabolism, and highlight how understanding the heterogeneity of cancer metabolism is fundamental to the development of effective metabolism-based therapeutic strategies. Deciphering how cancer cells utilize various nutrient resources will enable clinicians and researchers to pair specific chemotherapeutic agents with patients who are most likely to respond with positive outcomes, allowing for more cost-effective and personalized cancer therapeutic strategies. |
| car-t therapy for mantle cell lymphoma: The EBMT Handbook Nicolaus Kröger, Mohamad Mohty, Carlo Dufour, 2020-10-08 This Open Access edition of the European Society for Blood and Marrow Transplantation (EBMT) handbook addresses the latest developments and innovations in hematopoietic stem cell transplantation and cellular therapy. Consisting of 93 chapters, it has been written by 175 leading experts in the field. Discussing all types of stem cell and bone marrow transplantation, including haplo-identical stem cell and cord blood transplantation, it also covers the indications for transplantation, the management of early and late complications as well as the new and rapidly evolving field of cellular therapies. This book provides an unparalleled description of current practices to enhance readers' knowledge and practice skills. This work was published by Saint Philip Street Press pursuant to a Creative Commons license permitting commercial use. All rights not granted by the work's license are retained by the author or authors. |
| car-t therapy for mantle cell lymphoma: Normal and Malignant B-Cell Mourad Aribi, 2020-02-26 Normal and Malignant B-Cell is a collection of harmonious chapters contributed by different authors. This book sets out to describe the B-cell during different stages of ontogeny and the molecular mechanisms of its antigen receptor diversity. It also discusses the main clinical and etiopathogenic aspects when it is transformed into a malignant cell. The book will be interesting and useful for clinicians, biologists, researchers, teachers, and graduate students of both doctoral and master's degrees in the field of immunology. |
| car-t therapy for mantle cell lymphoma: Protein Engineering Huimin Zhao, 2021-08-23 A one-stop reference that reviews protein design strategies to applications in industrial and medical biotechnology Protein Engineering: Tools and Applications is a comprehensive resource that offers a systematic and comprehensive review of the most recent advances in the field, and contains detailed information on the methodologies and strategies behind these approaches. The authors—noted experts on the topic—explore the distinctive advantages and disadvantages of the presented methodologies and strategies in a targeted and focused manner that allows for the adaptation and implementation of the strategies for new applications. The book contains information on the directed evolution, rational design, and semi-rational design of proteins and offers a review of the most recent applications in industrial and medical biotechnology. This important book: Covers technologies and methodologies used in protein engineering Includes the strategies behind the approaches, designed to help with the adaptation and implementation of these strategies for new applications Offers a comprehensive and thorough treatment of protein engineering from primary strategies to applications in industrial and medical biotechnology Presents cutting edge advances in the continuously evolving field of protein engineering Written for students and professionals of bioengineering, biotechnology, biochemistry, Protein Engineering: Tools and Applications offers an essential resource to the design strategies in protein engineering and reviews recent applications. |
| car-t therapy for mantle cell lymphoma: Heparanase Israel Vlodavsky, Ralph D. Sanderson, Neta Ilan, 2020-04-09 Written by internationally recognized leaders in Heparanase biology, the book’s eight chapters offer an opportunity for scientists, clinicians and advanced students in cell biology, tumor biology and oncology to obtain a comprehensive understanding of Heparanase’s multifaceted activities in cancer, inflammation, diabetes and other diseases, as well as its related clinical applications. Proteases and their involvement in cancer progression have been well addressed and documented; however, the emerging premise presented within this book is that Heparanase is a master regulator of aggressive cancer phenotypes and crosstalk with the tumor microenvironment. This endoglycosidase contributes to tumor-mediated remodeling of the extracellular matrix and cell surfaces, augmenting the bioavailability of pro-tumorigenic and pro-inflammatory growth factors and cytokines that are bound to Heparan sulfate. Compelling evidence ties Heparanase with all steps of tumor progression including tumor initiation, growth, angiogenesis, metastasis, and chemoresistance, supporting the notion that Heparanase is an important contributor to the poor outcome of cancer patients and a validated target for therapy. Unlike Heparanase, heparanase-2, a close homolog of Heparanase, lacks enzymatic activity, inhibits Heparanase, and regulates selected genes that promote normal differentiation and tumor suppression. Written by internationally recognized leaders in Heparanase biology, this volume presents a comprehensive understanding of Heparanase’s multifaceted activities in cancer, inflammation, diabetes and other diseases, as well as its related clinical applications to scientists, clinicians and advanced students in cell biology, tumor biology and oncology. |
| car-t therapy for mantle cell lymphoma: Co-signal Molecules in T Cell Activation Miyuki Azuma, Hideo Yagita, 2019-11-22 This book equips young immunologists and health professionals with a clear understanding of the fundamental concepts and roles of co-signal molecules and in addition presents the latest information on co-stimulation. The first part of the book is devoted to co-signal molecules and the regulation of T cells. Following an initial overview, subsequent chapters examine each co-signal molecule in turn and discuss the mechanisms by which co-signal molecules regulate the different types of T cell. The second part covers various clinical applications, including in autoimmune disease, neurological disorders, transplantation, graft-versus-host disease, and cancer immunotherapy. To date, co-stimulation blockade and co-inhibition blockade have shown beneficial effects and many additional clinical trials targeting co-signal molecules are ongoing. The mechanisms underlying these successful treatments are explained and the future therapeutic potential in the aforementioned diseases is evaluated. Co-signal Molecules in T Cell Activation will be a valuable reference guide to co-stimulation for basic and clinical researchers in the fields of both immunology and pharmaceutical science. |
| car-t therapy for mantle cell lymphoma: Histopathology of Non-Hodgkin's Lymphomas Karl Lennert, Alfred C. Feller, 1990 |
| car-t therapy for mantle cell lymphoma: Lymphoma Anas Younes, Bertrand Coiffier, 2013-05-17 Recently, understanding the molecular pathogenesis of malignant lymphomas has led to improvement in the diagnostic precision and to the identification of a variety of molecular therapeutic targets. In addition, new drugs have been approved in the US and Europe, resulting in changes in the standard of care of several types of lymphoid malignancies. Comprehensive in scope and developed by a team of internationally renowned authors, Lymphoma: Diagnosis and Treatment provides a timely update on the most important advances in the biology, diagnosis, and therapy of lymphomas. As part of the Current Clinical Oncology series, Lymphoma: Diagnosis and Treatment will be of value to medical oncologists, hematologists, radiation oncologists, and all physicians involved in the care of patients with lymphoid malignancies. |
| car-t therapy for mantle cell lymphoma: Flow Cytometry in Evaluation of Hematopoietic Neoplasms Sindhu Cherian, Brent Wood, 2012 Flow Cytometry in Evaluation of Hematopoietic Neoplasms: A Case-Based Approach is a practical, case-based guide to flow cytometric analysis in the workup of hematopoietic neoplasms presenting in the peripheral blood, marrow, lymphoid tissue, and extranodal sites. Using multi-color techniques pioneered by Brent Wood, the text demonstrates a unique approach to diagnosis of hematopoietic malignancies as well as identification of small abnormal populations in the posttherapy setting (minimal residual disease testing). The publication contains an introduction to immunophenotypic changes seen in normal hematopoiesis along with an overview of the evaluation of lymphomas, leukemias, and myeloid stem- cell neoplasms. These concepts are further illustrated by a series of 36 cases, each dedicated to a specific disease entity. Each case provides detailed, full-color images of flow cytometric dot plots that clearly outline the features of the disease, accompanied by a clinical history and thorough discussion, enabling readers to develop and work through a differential diagnosis and recognize potential diagnostic pitfalls. Take-home points for each case emphasize critical concepts in flow cytometric diagnosis. Flow Cytometry in Evaluation of Hematopoietic Neoplasms provides pathologists, residents, laboratory technologists, and hematologists with both a study guide and an atlas for regular consultation in the clinical flow cytometry laboratory. The 2008 World Health Organization (WHO) classification system, French-American-British (FAB) classifications, and 2006 Bethesda Consensus recommendations are incorporated in the text. |
| car-t therapy for mantle cell lymphoma: The Peripheral T-Cell Lymphomas Owen A. O'Connor, Won Seog Kim, Pier L. Zinzani, 2021-06-01 THE PERIPHERAL T-CELL LYMPHOMAS Provides a comprehensive look at Peripheral T-Cell lymphomas, including the group’s unique geographic distribution, underlying genetics, and novel treatments Peripheral T-Cell lymphomas (PTCL) are a diverse group of lymphoid malignancies that develop from mature T cells and natural killer (NK) cells. PTCL represent 10-15% of all cases of non-Hodgkin lymphoma in the US, and up to 20-25% of cases in South America, Asia, and other regions around the world. The role of different etiologic factors and the variation of geographic distribution makes PTCL one of the most difficult types of cancer to understand and treat. For the first time in a single volume, The Peripheral T-Cell Lymphomas presents a comprehensive survey of this complex and rare group of blood cancers. Featuring contributions from an international team of leading authorities in the various aspects of PTCL, this authoritative text covers biology, epidemiology, classification, approved and emerging drugs, molecular genetics, and more. Detailed clinical chapters address diagnosis, prognosis, and treatment of each of the major PTCL subtypes identified in the 2018 WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues. This much-needed resource: Covers the biological basis, epidemiology, classification, and treatment of PTCL Discusses the future of the field, including global collaboration efforts and novel approaches to PCTL Explores the role of biologics in PTCL and autologous and allogeneic stem-cell transplantation Offers new insights on molecular pathogenesis, innovative therapeutics, and novel drug combinations Features contributions from the Chairs The T-Cell Lymphoma Forum: the world’s largest meeting focused on PTCL Reflecting the unique epidemiology and genetic diversity of the PTCL, The Peripheral T-Cell Lymphomas is an indispensable source of data, insight, and references for the medical community, particularly oncologists and hematologists in both training and practice. |
| car-t therapy for mantle cell lymphoma: Treatment of Leukemia and Lymphoma David A. Scheinberg, Joseph G. Jurcic, 2004-10-30 New Treatments of Leukemia and Lymphoma describes the most important advances in the therapy of hematopoietic cancers that have been derived from recent discoveries in cancer cell biology, kinase biochemistry, and immunology. Detailed descriptions of the large number of new and effective agents that have recently become available for the treatment of leukemias and lymphomas as well as an understanding of their mechanisms of action and their integration into current therapy are provided. A number of experimental drug reagents currently in clinical investigation are also discussed. The therapies include conventional anti-metabolites, monoclonal antibodies directed to cell surface receptors, antibodies tagged with toxins and radiopharmaceuticals, inhibitors of specific kinases, stem cell transplants, and engineered T-cells designed to selectively target hematopoietic cancers. The contents of the book will allow practitioners and investigators alike to understand what is current and state of the art as well as what to look for in the future.* Provides an up-to-date, state of the art discussion of a rapidly changing field * Great breadth covering conventional chemotherapeutic agents, biologic agents such as antibodies, novel small molecule inhibitors and genetically engineered cells * Written by international experts in each of the fields |
| car-t therapy for mantle cell lymphoma: Guidelines for Preparing Patent Landscape Reports World Intellectual Property Organization, 2015-08-24 These Guidelines are designed both for general users of patent information, as well as for those involved in producing Patent Landscape Reports (PLRs). They provide step-by-step instructions on how to prepare a PLR, as well as background information such as objectives, patent analytics, concepts and frameworks. |
| car-t therapy for mantle cell lymphoma: Immunopharmacogenomics Yusuke Nakamura, 2015-09-18 This book proposes immunogenomics, or immunopharmacogenomics, as the next-generation big science to uncover the role that the immune system plays in the pathogenesis of many diseases, by summarizing the importance of the deep sequencing of T-cell and B-cell receptors. Immunogenomics/immunopharmacogenomics, a genetic characterization of the immune system made possible by next-generation sequencing (NGS), will be important for the further understanding of the pathogenesis of various disease conditions. Abnormal immune responses in the body lead to development of autoimmune diseases and food allergies. Rejection of recipient cells and tissues, as well as severe immune reactions to donor cells, is also the result of uncontrolled immune responses in the recipient body. There have been many reports indicating that activated immune responses caused by the interaction of drugs and HLA are present in drug-induced skin hypersensitivity and liver toxicity. The importance of the host immune responses has been recognized in cancer treatments, not only for immunotherapy but also for cytotoxic agents and molecular targeted drugs. Hence, characterization of the T-cell receptor and B-cell receptor repertoire by means of NGS deep sequencing will ultimately make possible the identification of the molecular mechanisms that underlie various diseases and drug responses. In addition, this approach may contribute to the identification of antigens associated with the onset or progression of autoimmune diseases as well as food allergies. Although the germline alterations and somatic mutations have been extensively analyzed, changes or alterations of the immune responses during the course of various disease conditions or during various treatments have not been analyzed. It is also clear that computational analyses to draw meaningful inferences of functional recognition receptors on the immune cells remain a huge challenge. |
| car-t therapy for mantle cell lymphoma: SITC’s Guide to Managing Immunotherapy Toxicity Marc S. Ernstoff, MD, Igor Puzanov, MD, MSCI, FACP, Caroline Robert, MD, PhD, Adi M. Diab, MD, Peter M. Hersey, MD, PhD, 2019-03-15 The Society for Immunotherapy of Cancer's handbook,SITC’s Guide to Managing Immunotherapy Toxicity, is a practical reference to managing side effects associated with FDA-approved cancer immunotherapy drugs. Separated into two parts, Part I contains chapter-based overviews of immune checkpoint inhibitors in the clinic, starting with anti-CTLA4 agents, anti-PD1/PD-L1 agents, and approved immunotherapeutic combinations. These chapters cover relevant mechanisms of action, indications, and toxicities seen while combating early, advanced, and metastatic stages in cancer patients. Part II is structured by common and uncommon toxicities that affect major organ sites throughout the body. It begins with a general summary of principles and management options followed by chapters focusing on specific toxicities such as rash and mucosal irritation, muscle and joint toxicity, diarrhea and colitis, pneumonitis, endocrine toxicities, neurological toxicities, cardiac toxicity, renal toxicity, hematologic toxicity, and ocular toxicities. Each chapter provides guidance on how to assess and treat the toxicity and how to support the patient through acute and chronic effects with detailed summary tables for quick reference. Part II concludes with chapters covering management of special patient populations, including patients with autoimmune disease and geriatric patients, treatment and management of fatigue, and a final chapter dedicated to cost effectiveness and the toll of financial toxicity on patients and caregivers. With chapters written by world-recognized leaders in the immuno-oncology field, this text provides thorough coverage of the toxicity and management of adverse effects for immune checkpoint inhibitors. It is an indispensable resource for clinical oncologists, emergency physicians, hospitalists and other medical practitioners in both the hospital and community clinic settings, especially as the use of immune checkpoint inhibitors becomes a fixture in oncology care. Key Features: Outlines strategies for treating high-risk patients facing an acute or chronic side effect to immunotherapy Provides numerous tables that condense and highlight pertinent information for quick reference Describes the various clinical presentations and toxic reactions caused by immunotherapy Purchase includes access to the eBook for use on most mobile devices or computer |
| car-t therapy for mantle cell lymphoma: Handbook of Hematologic Malignancies David A. Sallman, Ateefa Chaudhury, Johnny Nguyen, Ling Zhang, Alan F. List, 2017 MDS/MPN With Ring Sideroblasts and Thrombocytosis |
| car-t therapy for mantle cell lymphoma: Oncoimmunology Laurence Zitvogel, Guido Kroemer, 2017-12-13 In this book, leading experts in cancer immunotherapy join forces to provide a comprehensive guide that sets out the main principles of oncoimmunology and examines the latest advances and their implications for clinical practice, focusing in particular on drugs with FDA/EMA approvals and breakthrough status. The aim is to deliver a landmark educational tool that will serve as the definitive reference for MD and PhD students while also meeting the needs of established researchers and healthcare professionals. Immunotherapy-based approaches are now inducing long-lasting clinical responses across multiple histological types of neoplasia, in previously difficult-to-treat metastatic cancers. The future challenges for oncologists are to understand and exploit the cellular and molecular components of complex immune networks, to optimize combinatorial regimens, to avoid immune-related side effects, and to plan immunomonitoring studies for biomarker discovery. The editors hope that this book will guide future and established health professionals toward the effective application of cancer immunology and immunotherapy and contribute significantly to further progress in the field. |
| car-t therapy for mantle cell lymphoma: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues World Health Organization, 2001 This is the third volume in the new World Health Organization series on histological and genetic typing of tumours. Tumours of the haematopoietic and lymphoid tissues are covered. This was a collaborative project of the European Association for Haematolpathology and the Society for Haematopathology and others. The WHO classification is based on the principles defined in the Revised European-American Classification of Lymphoid Neoplasms (REAL) classification. Over 50 pathologists from around the world were involved in the project and proponents of all major lymphoma and leukaemia classifications have agreed to accept the WHO as the standard classification of haematological malignancies. So this classification represents the first true world wide concensus of haematologic malignancies. Colour photographs, magnetic resonance and ultrasound images and CT scans are included. |
| car-t therapy for mantle cell lymphoma: Withrow and MacEwen's Small Animal Clinical Oncology Stephen J. Withrow, Rodney Page, David M. Vail, 2012-11-13 With a unique focus on the most effective interventional techniques, Withrow & MacEwen's Small Animal Clinical Oncology, 5th Edition tells the full story of cancer in dogs and cats - what it is, how to diagnose it, and how to treat many of the most common cancers encountered in clinical practice. Nearly 500 color photographs, diagrams, x-rays, and gross views depict the clinical manifestations of various cancers. This edition covers the latest advances in clinical oncology, including chemotherapy, surgical oncology, and diagnostic techniques. With contributions from 65 veterinary oncology experts, this authoritative reference is a must-have for current, evidence-based therapeutic strategies on canine and feline oncology. I really love this book. If you are interested in veterinary oncology, have a flick through this book online or at a conference when you get the chance. I hope that you agree with me that this is the definitive oncology reference source for the early 21st century and that you feel compelled to buy it. Your patients will thank you for it. Reviewed by: Gerry Polton MA VetMB MSc(Clin Onc) DipECVIM-CA(Onc) MRCVS, UK Date: July 2014 Cutting-edge information on the complications of cancer, pain management, and the latest treatment modalities prepares you to diagnose and treat pets with cancer rather than refer cases to a specialist. A consistent format for chapters on body system tumors includes coverage of incidence and risk factors, pathology, natural behavior of tumors, history and clinical signs, diagnostic techniques and workup, treatment options, and prognosis for specific malignancies. A systems approach to the diagnosis and management of cancer facilitates access to information about the many malignancies affecting small animal patients. Nearly 500 color images provide accurate depictions of specific diseases and procedures. Helpful drug formularies provide quick access to information on indications, toxicities, and recommended dosages for chemotherapeutic and analgesic drugs used in cancer treatment. Expert contributors provide in-depth coverage of the most current information in his or her respective specialty in veterinary oncology. Chemotherapy protocols are included when case studies prove clinical efficacy. Discussion of compassion and supportive care for the management of pain, nutritional needs, and grief includes methods for handling the pet's pain and nutritional complications as well as the pet owner's grief when treatment is not successful. Thoroughly UPDATED chapters cover the most recent changes in the clinical management of melanoma, mast cell tumors, tumors of the skeletal system, tumors of the endocrine system, tumors of the mammary gland, urinary cancers, nervous system cancers, lymphoma, and histiocytic diseases. NEW Clinical Trials and Developmental Therapeutics chapter discusses the various phases of clinical trials as well as current challenges and opportunities in oncology drug development. NEW! A focus on the best recommended treatment options highlights therapeutic strategies that have been vetted by veterinary oncology experts. NEW co-author Dr. Rodney L. Page adds his valuable perspective, expertise, and research experience. |
| car-t therapy for mantle cell lymphoma: Cell and Gene Therapies Miguel-Angel Perales, Syed A. Abutalib, Catherine Bollard, 2018-11-27 In this book, experts in the field express their well-reasoned opinions on a range of complex, clinically relevant issues across the full spectrum of cell and gene therapies with the aim of providing trainee and practicing hematologists, including hematopoietic transplant physicians, with information that is relevant to clinical practice and ongoing research. Each chapter focuses on a particular topic, and the concise text is supported by numerous working tables, algorithms, and figures. Whenever appropriate, guidance is provided regarding the availability of potentially high-impact clinical trials. The rapid evolution of cell and gene therapies is giving rise to numerous controversies that need to be carefully addressed. In meeting this challenge, this book will appeal to all residents, fellows, and faculty members responsible for the care of hematopoietic cell transplant patients. It will also offer a robust, engaging tool to aid vital activities in the daily work of every hematology and oncology trainee. |
| car-t therapy for mantle cell lymphoma: Mechanisms of Drug Resistance in Neoplastic Cells Paul V. Woolley, Kenneth D. Tew, 2013-10-22 Bristol-Myers Cancer Symposia, Volume 9: Mechanisms of Drug Resistance in Neoplastic Cells provides information on both basic scientific and clinical studies on the causes and implications of tumor cell resistance to common antineoplastic agents. The book describes the colon cancer as a model for resistance to antineoplastic drugs; mathematical modeling of drug resistance; and the mechanism of induced gene amplification in mammalian cells. The text also discusses the cellular concomitants of multidrug resistance; resistance to alkylating agents; and the phosphoprotein and protein kinase C changes in human multidrug-resistant cancer cells. Novel drugs that affect glutathione metabolism; the regulation of genes encoding drug-metabolizing enzymes in normal and preneoplastic tissues; and the relevance of glutathione S-transferases to anticancer drug resistance are also considered. The book further tackles the cellular resistance to cyclophosphamide; the preclinical and clinical experiences with drug combinations designed to inhibit DNA repair in resistant human tumor cells; and the modification of the cytotoxicity of DNA-directed chemotherapeutic agents by polyamine depletion. The text also demonstrates multidrug resistance and the circumvention of resistance. Oncologists, molecular biologists, biochemists, geneticists, and pharmacologists will find the book invaluable. |
| car-t therapy for mantle cell lymphoma: Cancer Incidence and Survival Among Children and Adolescents , 1999 |
| car-t therapy for mantle cell lymphoma: Brain Tumor Imaging Elke Hattingen, Ulrich Pilatus, 2015-09-02 This book describes the basics, the challenges and the limitations of state of the art brain tumor imaging and examines in detail its impact on diagnosis and treatment monitoring. It opens with an introduction to the clinically relevant physical principles of brain imaging. Since MR methodology plays a crucial role in brain imaging, the fundamental aspects of MR spectroscopy, MR perfusion and diffusion-weighted MR methods are described, focusing on the specific demands of brain tumor imaging. The potential and the limits of new imaging methodology are carefully addressed and compared to conventional MR imaging. In the main part of the book, the most important imaging criteria for the differential diagnosis of solid and necrotic brain tumors are delineated and illustrated in examples. A closing section is devoted to the use of MR methods for the monitoring of brain tumor therapy. The book is intended for radiologists, neurologists, neurosurgeons, oncologists and other scientists in the biomedical field with an interest in neuro-oncology. |
| car-t therapy for mantle cell lymphoma: Immunologic Concepts in Transfusion Medicine Robert W Maitta, 2019-08-27 Immunological Concepts in Transfusion Medicine provides a thorough discussion of the immune aspects of blood component transfusion, with in-depth information on the intricacies of immune responses to blood components and the immune processes that may be initiated in response to blood exposure. Written to increase knowledge and awareness of immune challenges such as alloimmunization and transfusion-related acute lung injury, this title bridges current basic scientific discoveries and the potential effects seen in blood recipients. - Complies the knowledge and expertise of Dr. Robert Maitta, an expert in immune responses and antibody function/structure studies. - Helps clinicians in the daily practice of caring for patients in need of transfusion support, as well as physicians in training when considering utilizing blood transfusions in a limited scope or in the setting of massive transfusion. - Includes an immunology primer as an introduction to in-depth chapters covering allergic immune reactions to blood components, transfusion-related immunomodulation, fetal and neonatal alloimmune thrombocytopenia and neonatal neuthropenia, complications of haploidentical and mismatched HSC transplantation, chimeric antibody receptor therapies, and much more. - Consolidates today's available information on this timely topic into a single, convenient resource. |
| car-t therapy for mantle cell lymphoma: Adoptive Immunotherapy Burkhard Ludewig, Matthias W. Hoffmann, 2008-02-02 An authoritative collection of optimal techniques for producing and characterizing the immunologically active cells and effector molecules now gaining wide use in the clinical treatment of patients. Taking advantage of the latest technologies, the authors present readily reproducible experimental protocols for the study of dendritic cells, T cells, monoclonal antibodies, and bone marrow transplantation. The emphasis is on preclinicical and clinical applications and on the progress of selected approaches in clinical trials. Additional chapters cover the molecular definition of target antigens, mathematical modeling approaches to immunotherapy, and the utilization of regulatory T cells. The protocols make it possible to study the adoptive transfer of tailored antigen-specific immune cells and to improve the clinical application of adoptive immunotherapy. |
| car-t therapy for mantle cell lymphoma: Pediatric Lymphomas Howard J. Weinstein, Melissa M. Hudson, Michael P. Link, 2007-01-20 This is a comprehensive textbook of Hodgkin's and non-Hodgkin's lymphomas written by leaders in the field of childhood lymphomas. It includes clinical, pathologic and molecular biology of each subtype of lymphoma. The pathology chapters are comprehensive and include excellent photographs. The book is at the level of subspecialists in pediatric hematology and oncology, radiation oncology, pediatric surgery and hematopathology. |
| car-t therapy for mantle cell lymphoma: Current Strategies in Cancer Gene Therapy Wolfgang Walther, 2017-01-17 This book describes important developments and emerging trends in experimental and clinical cancer gene therapy. It reflects the tremendous advances made over recent years with respect to immunogenes, suicide genes and gene correction therapies, as well as in gene suppression and miRNA therapies. Many of the described strategies focus on the generation of more efficient and specific means of attack at known and novel cellular targets associated with tumor development and progression. The book also details parallel improvements in vector design, vector delivery, and therapeutic efficacy. It offers readers a stimulating, broad overview of advances in the field, linking experimental strategies to their clinical applications. |
| car-t therapy for mantle cell lymphoma: Cancer-Associated Thrombosis Alok A. Khorana, Charles W. Francis, 2007-09-26 Showcasing the expertise of top-tier specialists who contributed to the newly released guidelines for the care of thrombosis in cancer patients, this exciting guide was written and edited by members of the American Society of Clinical Oncology panel, (ASCO), on the prevention and treatment of cancer-associated thrombosis, among others, and provides |
| car-t therapy for mantle cell lymphoma: Mantle Cell Lymphoma, an Issue of Hematology/Oncology Clinics of North America, Volume 34-5 John P. Leonard, 2020-10-28 This issue of Hematology/Oncology Clinics, Guest Edited by Dr. John P. Leonard, is devoted to Mantle Cell Lymphoma. This issue is one of six selected each year by our series Consulting Editors, George P. Canellos and Edward J. Benz. Topics discussed in this important issue include: Molecular pathogenesis of Mantle Cell Lymphoma; MCL and cell cycle dysregulation; Heterogeneity in MCL biology and outcomes; Watch and wait in mantle cell lymphoma; Limited stage mantle cell lymphoma; Initial and consolidation therapy for younger patients with MCL; Approach to the initial treatment of older patients with MCL; Current and future approaches to the use of minimal residual disease monitoring in the treatment of patients with MCL; Bruton's Tyrosine Kinase inhibitors for treatment of Mantle Cell Lymphoma; BTKi resistance in MCL; Blastoid MCL; Allogeneic transplant and CAR-T cell therapy in MCL; Quality of life considerations and chronic therapy in management of patients with MCL; and Key clinical and translational research questions. |
| car-t therapy for mantle cell lymphoma: Introduction to Lymphoma , 2023 |
| car-t therapy for mantle cell lymphoma: CAR T-Cell, An Issue of Hematology/Oncology Clinics of North America, E-Book Caron A Jacobson, Parth S. Shah, 2023-10-12 In this issue of Hematology/Oncology Clinics, guest editors Drs. Caron A. Jacobson and Parth S. Shah bring their considerable expertise to the topic of CAR T-Cell Therapy. Top experts in the field discuss the multiple ways CAR T-cell therapy can be used to help fight a variety of cancers, such as diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, mantle cell lymphoma, multiple myeloma, and B-cell acute lymphoblastic leukemia (ALL). - Contains 12 practice-oriented topics including CAR T-cells in aggressive B-cell lymphomas; CAR T-cells in multiple myeloma; CAR T-cells in AML; mechanisms of resistance of CAR T-cell therapy; the role of CAR T-cell therapy in the era of bispecific antibodies; and more. - Provides in-depth clinical reviews on CAR T-cell therapy, offering actionable insights for clinical practice. - Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews. |
| car-t therapy for mantle cell lymphoma: Car T-Cell T, an Issue of Hematology/Oncology Clinics of North America: Volume 37-6 Caron A. Jacobson, Parth S. Shah, 2023-12-28 In this issue of Hematology/Oncology Clinics, guest editors Drs. Caron A. Jacobson and Parth S. Shah bring their considerable expertise to the topic of CAR T-Cell Therapy. Top experts in the field discuss the multiple ways CAR T-cell therapy can be used to help fight a variety of cancers, such as diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, mantle cell lymphoma, multiple myeloma, and B-cell acute lymphoblastic leukemia (ALL). Contains 12 practice-oriented topics including CAR T-cells in aggressive B-cell lymphomas; CAR T-cells in multiple myeloma; CAR T-cells in AML; mechanisms of resistance of CAR T-cell therapy; the role of CAR T-cell therapy in the era of bispecific antibodies; and more. Provides in-depth clinical reviews on CAR T-cell therapy, offering actionable insights for clinical practice. Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews. |
| car-t therapy for mantle cell lymphoma: DeVita, Hellman, and Rosenberg's Cancer Vincent T DeVita Jr, Steven A Rosenberg, Theodore S Lawrence, 2022-09-21 The standard-setting text in oncology for 40 years, DeVita, Hellman and Rosenberg’s Cancer: Principles and Practice of Oncology, 12th Edition, provides authoritative guidance and strategies for managing every type of cancer by stage and presentation. Drs. Vincent T. DeVita, Jr., Theodore S. Lawrence, and Steven A. Rosenberg oversee an outstanding team of expert contributing authors who keep you up to date and fully informed in this fast-changing field. This award-winning reference is also continually updated on Health Library and VitalSource platforms for the life of the edition. |
| car-t therapy for mantle cell lymphoma: MCB: CAR T Cells: Development, Characterization and Applications Lorenzo Galluzzi, Sheila Spada, 2022-02-11 MCB: CAR T Cells: Development, Characterization and Applications, Volume 167 in the Methods in Cell Biology series, highlights new advances in the field, with this new volume presenting interesting chapters on a variety of timely topics, including High-efficiency of genetic modification using CRISPR/Cpf1 system for engineered CAR T-cell therapy, Determination of the Biodistribution of Chimeric Antigen Receptor-Modified T Cells against CD19 in NSG Mice, Generation of CAR-T cells using lentiviral vectors, Generation of CAR T-cells using ?-retroviral vector, Flow cytometry detection and quantification of CAR T cells into solid tumors, Evaluation of CAR-T Cell Cytotoxicity: Real-Time Impedance-Based Analysis, and much more. - Provides the authority and expertise of leading contributors from an international board of authors - Presents the latest release in the Methods in Cell Biology series - Includes the latest information on the topic of development, characterization and applications in CAR T Cells |
| car-t therapy for mantle cell lymphoma: Novel therapies for indolent lymphomas in the cellular therapy era Narendranath Epperla, Sairah Ahmed, 2023-11-06 |
r/Cars - For Car Enthusiasts - Reddit
r/Cars is the largest automotive enthusiast community on the Internet. We're Reddit's central hub for vehicle-related discussion, industry news, reviews, projects, DIY guides, advice, stories, …
Former CarMax employee here. If you plan to go in for an ... - Reddit
Feb 3, 2021 · Where younger an estimated value and when you come in our car buyer puts in his notes and we show you side by side. Where you thought you were and didn't mention that …
How much do car salesmen REALLY make? : r/askcarsales - Reddit
Apr 26, 2022 · Is 6 figures in car sales the norm? EDIT: 25M, single, no kids. Currently in civil engineering with $78k salary in LCOL area (central texas). Seems like folks are making well …
Hoseheadforums.com Home
Aug 17, 2013 · Bodnar Motorsports building new car for 2019 viewed (10751) Wicked Energy Gum to Sponsor the Northwest Focus Midget Series viewed (8765) Heartland Motorsports …
best places to search for used cars : r/cars - Reddit
Sep 7, 2018 · r/Cars is the largest automotive enthusiast community on the Internet. We're Reddit's central hub for vehicle-related discussion, industry news, reviews, projects, DIY …
Car dealership scratch-off mailer scam (Update) : r/Scams - Reddit
Mar 12, 2019 · I posted a couple of days ago about a scratch-off contest mailer that I had received from a local car dealership. My "game piece" seemed to indicate that I had won the Grand …
Nothing Under - Reddit
r/NothingUnder: Dresses and clothing with nothing underneath. Women in outfits perfect for flashing, easy access, and teasing men.
What’s the best auto insurance? : r/Insurance - Reddit
I also know that being young and driving a newer car is the reason behind all this, but any advice/tips about all this is much needed! Is the monthly rate really normal for someone my …
HoseHeads Sprint Car General Forum - Oval Track Racing Forums
4 days ago · Forum: HoseHeads Sprint Car General Forum Moderators: dirtonly / dmantx / hosehead First
I've been scouring the internet for a working download link to
Aug 26, 2023 · 31 votes, 30 comments. 36K subscribers in the E90 community. Hub for all BMW 3 series, 2006-2013. Anyone is welcome!
TIGIT is the central player in T-cell suppression associated …
Keywords: Mantle cell lymphoma, CAR T‑cell therapy, Relapse, T cell suppression, Myeloid‑derived suppressor cells, Immune checkpoint, TIGIT, Cytokines, Chemokines, Soluble …
Cellular Therapies for Mantle Cell Lymphoma
antigen receptor T cell (CAR T) therapy from the bench to the bedside, with brexucabtagene autoleucel being the ... T cell therapy Mantle cell lymphoma (MCL) is a subtype of B cell non …
Intrinsic immunosuppressive features of monocytes suppress …
of M2-like macrophage-derived inhibition of CAR-T19 in mantle cell lymphoma (MCL), as well as a potential target to enhance CAR-T19 efficacy. In preclinical models that recapit-ulated …
CAR T-cell therapy for follicular lymphoma and mantle cell …
other CAR T products for the treatment of these two diseases. CAR T-cell therapy for follicular lymphoma and mantle cell lymphoma Razan Mohty and Mohamed A. Kharfan-Dabaja Abstract: …
Pirtobrutinib and venetoclax combination overcomes …
mantle cell lymphoma (MCL), including inhibitors of Bruton. tyrosine kinase (BTK) and CD19-directed chimeric antigen. receptor (CAR) T-cell therapy, resistance and disease re-lapse …
LET’S TALK ABOUT CAR T-CELL THERAPY AS A TREATMENT …
Jan 29, 2024 · CAR T-CELL THERAPY AS A TREATMENT OPTION: BLOOD CANCERS Monalisa Ghosh, MD Clinical Associate Professor University of Michigan Health Ann Arbor, MI …
Mantle Cell Lymphoma - Leukemia & Lymphoma Society
Mantle cell lymphoma (MCL) is one of about 70 different subtypes of NHL. Knowing your disease subtype is important because the treatment approach is based on the subtype. For additional …
CAR-T cell therapy - Lymphoma Action
CAR-T cell therapy CAR-T cell therapy is a personalised treatment used for some types of lymphoma that have come back or not responded after previous treatment. ... • relapsed or …
Tecartus® (brexucabtagene autoleucel) T - OHSU
Oct 22, 2021 · Wang M, Munoz J, Goy A, et al. KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma. N Engl J Med. 2020 Apr 2;382(14):1331-1342. doi: …
Does Car T Therapy Work For Mantle Cell Lymphoma (PDF)
Does Car T Therapy Work For Mantle Cell Lymphoma: Mantle Cell Lymphoma, An Issue of Hematology/Oncology Clinics of North America,E-Book John P. Leonard,2020-09-11 This issue …
Management of adults and children receiving CAR T-cell …
CD19 chimeric antigen receptor T-cell (CAR-T) therapeutics are widely used for relapsed/refractory (r/r) B-cell malig-nancies including acute lymphoblastic leukemia (B-ALL), …
Does Car T Therapy Work For Mantle Cell Lymphoma Copy
Does Car T Therapy Work For Mantle Cell Lymphoma: Mantle Cell Lymphoma, An Issue of Hematology/Oncology Clinics of North America,E-Book John P. Leonard,2020-09-11 This issue …
Successful treatment of second-time CAR-T 19 therapy after …
ibrutinib and CAR-T 19 cell group after ibrutinib therapy with or without ibrutinib. Ibrutinib (4 μg/mL/day) was added to the CAR-T 19 cell culture system on the first day. Cell Counting Kit-8 …
Treatment patterns, health care resource utilization, and costs …
T-cell (CAR T) therapy helps patients’ immune systems attack their cancer. We compared CAR T with older treatments for patients whose MCL had returned or ... Mantle cell lymphoma (MCL) …
Does Car T Therapy Work For Mantle Cell Lymphoma
Does Car T Therapy Work For Mantle Cell Lymphoma: Blood and Marrow Transplant Handbook Richard T. Maziarz,Susan Schubach Slater,2015-04-20 This updated and expanded edition …
Does Car T Therapy Work For Mantle Cell Lymphoma [PDF]
Does Car T Therapy Work For Mantle Cell Lymphoma: Blood and Marrow Transplant Handbook Richard T. Maziarz,Susan Schubach Slater,2015-04-20 This updated and expanded edition …
A single center retrospective study on real world CAR T-cell …
Nov 18, 2024 · Patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL) and multiple myeloma have very poor outcomes (1–3). As a …
Does Car T Therapy Work For Mantle Cell Lymphoma (PDF)
Does Car T Therapy Work For Mantle Cell Lymphoma: Blood and Marrow Transplant Handbook Richard T. Maziarz,Susan Schubach Slater,2015-04-20 This updated and expanded edition …
Mantle Cell Lymphoma Lymphoma Australia (MCL) Fact Sheet
Mantle Cell Lymphoma (MCL) Introduction Mantle cell lymphoma (MCL) is a subtype of non-Hodgkin Lymphoma (NHL). If you’ve been diagnosed with MCL, you ... (CAR T-cell therapy) – …
Dana-Farber to offer first CAR T-cell therapy for mantle cell …
T-cell therapy for mantle cell lymphoma (MCL) represents a key advance for patients with relapsed or treatment-resistant forms of the disease, say Dana-Farber Cancer Institute …
New Directions for Mantle Cell Lymphoma in 2022
CAR T-cell therapy is advisable, as similar efficacy has been observed with CAR T-cell therapy across subgroups, including patients with a high-risk Mantle Cell Lymphoma International …
Does Car T Therapy Work For Mantle Cell Lymphoma …
Does Car T Therapy Work For Mantle Cell Lymphoma: Mantle Cell Lymphoma, An Issue of Hematology/Oncology Clinics of North America,E-Book John P. Leonard,2020-09-11 This issue …
A novel CAR-T cell product targeting CD74 is an
Conclusions Targeting CD74 with 74bbz CAR-T cells represents a new cell therapy to provide a potent and durable ... Mantle cell lymphoma (MCL) is an incurable subtype of
Car T Cell Therapy For Mantle Cell Lymphoma
car t cell therapy for mantle cell lymphoma: Mantle Cell Lymphoma, An Issue of Hematology/Oncology Clinics of North America,E-Book John P. Leonard, 2020-09-11 This …
Does Car T Therapy Work For Mantle Cell Lymphoma
Does Car T Therapy Work For Mantle Cell Lymphoma: Fast Facts: CAR T-Cell Therapy in Diffuse Large B-Cell Lymphoma R.J. Buka,D. Moloney,2021-09-30 Diffuse large B cell lymphoma …
Does Car T Therapy Work For Mantle Cell Lymphoma (2024)
Does Car T Therapy Work For Mantle Cell Lymphoma: Mantle Cell Lymphoma, An Issue of Hematology/Oncology Clinics of North America,E-Book John P. Leonard,2020-09-11 This issue …
Does Car T Therapy Work For Mantle Cell Lymphoma [PDF]
Does Car T Therapy Work For Mantle Cell Lymphoma: Mantle Cell Lymphoma, An Issue of Hematology/Oncology Clinics of North America,E-Book John P. Leonard,2020-09-11 This issue …
Management of chimeric antigen receptor T-cell-related …
Mantle cell lymphoma (MCL) is a mature B-cell lym-phoma, with biological and clinical heterogeneity, ... However, CAR-T cell therapy spreading, imposed the challenge of new …
Does Car T Therapy Work For Mantle Cell Lymphoma [PDF]
Does Car T Therapy Work For Mantle Cell Lymphoma: Fast Facts: CAR T-Cell Therapy in Diffuse Large B-Cell Lymphoma R.J. Buka,D. Moloney,2021-09-30 Diffuse large B cell lymphoma …
Does Car T Therapy Work For Mantle Cell Lymphoma [PDF]
Does Car T Therapy Work For Mantle Cell Lymphoma: Blood and Marrow Transplant Handbook Richard T. Maziarz,Susan Schubach Slater,2015-04-20 This updated and expanded edition …
Does Car T Therapy Work For Mantle Cell Lymphoma …
Does Car T Therapy Work For Mantle Cell Lymphoma: Fast Facts: CAR T-Cell Therapy in Diffuse Large B-Cell Lymphoma R.J. Buka,D. Moloney,2021-09-30 Diffuse large B cell lymphoma …
CAR T-cell therapy for B-cell lymphomas: clinical trial results …
CAR T-cell therapy have shown great activity and long-term remissions in poor-risk diffuse large B-cell lymphoma (DLBCL) when no other effective treatment options are available. ... Mantle …
A phase 1 trial of prizloncabtagene autoleucel, a CD19/CD20 …
phoma (FL), or mantle cell lymphoma (MCL). Although anti-CD19 CAR T-cell therapies have proven to be efficacious in patients with R/R B-NHL, ~20% of patients with LBCL and ~10% of …
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory …
1332 n engl j med 382;14 nejm.org April 2, 2020 The new england journal of medicine M antle-cell lymphoma is a B-cell non-Hodgkin’s lymphoma that gener-ally has an aggressive clinical …
Chimeric antigen receptor therapy meets mRNA technology
Jul 27, 2023 · ing the first US approval of such therapy in 2017, seven other CAR T cell products have reached the market (five in the USA and two in China) for the treatment of hematological …
Does Car T Therapy Work For Mantle Cell Lymphoma …
Does Car T Therapy Work For Mantle Cell Lymphoma: Mantle Cell Lymphoma, An Issue of Hematology/Oncology Clinics of North America,E-Book John P. Leonard,2020-09-11 This issue …
Chimeric Antigen Receptor T-Cells in Indolent Lymphoma, …
T-Cells in Indolent Lymphoma, Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia Parth S. Shah, MDa, Caron A. Jacobson, MDb,* ... CD19-directed CAR T-cell therapy has been …
The CDK9 inhibitor enitociclib overcomes resistance to BTK
Inhibitors of Bruton’s tyrosine kinase (BTKi) and chimeric antigen receptor T-cell (CAR-T) therapy targeting CD19 are paradigm-shifting advances in treating patients with aggressive mantle cell …
Mantle Cell Lymphoma: Relapsed/Refractory
Mantle cell lymphoma (MCL) is a rare type of B-cell non-Hodgkin lymphoma (NHL). It can occur in men and women of any age, but it most commonly affects men over 60 years old. MCL …
Successful treatment by CAR T-cells in multi-refractory …
Keywords Mantle cell lymphoma · CNS · Relapse · CAR T-cells Dear Editor, The management of relapse/refractory (R/R) mantle-cell ... [–31]. Chimeric antigen receptor (CAR) T-cell therapy …
Cell Therapy - SingHealth
• Mantle cell lymphoma (MCL) • Multiple myeloma (MM) Patients must have received at least two lines of ... CAR T-cell therapy, particularly in CAR-NK cell therapy. She has been instrumental …
TIGIT is the central player in T-cell suppression associated …
Keywords: Mantle cell lymphoma, CAR T‑cell therapy, Relapse, T cell suppression, Myeloid‑derived suppressor cells, Immune checkpoint, TIGIT, Cytokines, Chemokines, Soluble …
Mantle Cell Lymphoma: Updates in the Management of …
high-risk patients after BTK inhibitor therapy. 13 According to Dr. Shadman, this combination regimen can be used to temporarily maintain stable disease (before CAR T-cell therapy), but it …
Transplantation and Cellular Therapy - astctjournal.org
Chimeric antigen receptor T cell (CAR T) therapy has been integrated into treatment algorithms for acute leuke-mia, lymphoma, and, most recently, multiple myeloma. The number of clinical …
CAR T-cell therapy for relapsed or refractory mantle-cell …
KTE-X19, a CAR T-cell therapy, led to durable remission in patients with relapsed or refractory mantle-cell lymphoma. 74 patients with either relapsed or refractory mantle-cell lymphoma …
Clinical Perspective: Treatment of Aggressive B Cell
Clinical Perspective Clinical Perspective: Treatment of Aggressive B Cell Lymphomas with FDA-Approved CAR-T Cell Therapies Mark B. Leick, 1 ,23Marcela V. Maus, and Matthew J. …
Apheresis collection for chimeric antigen receptor T Cell …
the first CAR T cell products in 2017, several therapies have become available for the treatment of B-cell acute lymphoblastic leukemia, diffuse large B-cell lymphoma, mantle cell lymphoma, …
Post‐BTK inhibitor mantle cell lymphoma: When is CAR‐T …
refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor fail-ure in Europe: The SCHOLAR-2 retrospective chart review study. Br J Haematol 2023;202:749–759. KEYWORDS …
940 CAR T-Cell Therapy Services for Mantle Cell Lymphoma ...
Clinical documentation that supports the medical necessity criteria for CAR T-Cell Therapy Services for Mantle Cell Lymphoma (Brexucabtagene Autoleucel) must be submitted. If the …
